Literature DB >> 35191872

Tocilizumab: A Role for Biomarker-Directed Therapy?

Jeffrey R Strich1,2, Daniel S Chertow1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35191872      PMCID： PMC8867749          DOI： 10.1097/CCM.0000000000005281

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   9.296


× No keyword cloud information.
  10 in total

1.  Sepsis Subclasses: A Framework for Development and Interpretation.

Authors:  Kimberley M DeMerle; Derek C Angus; J Kenneth Baillie; Emily Brant; Carolyn S Calfee; Joseph Carcillo; Chung-Chou H Chang; Robert Dickson; Idris Evans; Anthony C Gordon; Jason Kennedy; Julian C Knight; Christopher J Lindsell; Vincent Liu; John C Marshall; Adrienne G Randolph; Brendon P Scicluna; Manu Shankar-Hari; Nathan I Shapiro; Timothy E Sweeney; Victor B Talisa; Benjamin Tang; B Taylor Thompson; Ephraim L Tsalik; Tom van der Poll; Lonneke A van Vught; Hector R Wong; Sachin Yende; Huiying Zhao; Christopher W Seymour
Journal:  Crit Care Med       Date:  2021-05-01       Impact factor: 7.598

Review 2.  Role of C-Reactive Protein at Sites of Inflammation and Infection.

Authors:  Nicola R Sproston; Jason J Ashworth
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

3.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Authors:  Daniel E Leisman; Lukas Ronner; Rachel Pinotti; Matthew D Taylor; Pratik Sinha; Carolyn S Calfee; Alexandre V Hirayama; Fiore Mastroiani; Cameron J Turtle; Michael O Harhay; Matthieu Legrand; Clifford S Deutschman
Journal:  Lancet Respir Med       Date:  2020-10-16       Impact factor: 30.700

4.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

Authors:  Anthony C Gordon; Paul R Mouncey; Farah Al-Beidh; Kathryn M Rowan; Alistair D Nichol; Yaseen M Arabi; Djillali Annane; Abi Beane; Wilma van Bentum-Puijk; Lindsay R Berry; Zahra Bhimani; Marc J M Bonten; Charlotte A Bradbury; Frank M Brunkhorst; Adrian Buzgau; Allen C Cheng; Michelle A Detry; Eamon J Duffy; Lise J Estcourt; Mark Fitzgerald; Herman Goossens; Rashan Haniffa; Alisa M Higgins; Thomas E Hills; Christopher M Horvat; Francois Lamontagne; Patrick R Lawler; Helen L Leavis; Kelsey M Linstrum; Edward Litton; Elizabeth Lorenzi; John C Marshall; Florian B Mayr; Daniel F McAuley; Anna McGlothlin; Shay P McGuinness; Bryan J McVerry; Stephanie K Montgomery; Susan C Morpeth; Srinivas Murthy; Katrina Orr; Rachael L Parke; Jane C Parker; Asad E Patanwala; Ville Pettilä; Emma Rademaker; Marlene S Santos; Christina T Saunders; Christopher W Seymour; Manu Shankar-Hari; Wendy I Sligl; Alexis F Turgeon; Anne M Turner; Frank L van de Veerdonk; Ryan Zarychanski; Cameron Green; Roger J Lewis; Derek C Angus; Colin J McArthur; Scott Berry; Steve A Webb; Lennie P G Derde
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

5.  Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.

Authors:  Eric J Rubin; Dan L Longo; Lindsey R Baden
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

6.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.

Authors:  Ivan O Rosas; Norbert Bräu; Michael Waters; Ronaldo C Go; Bradley D Hunter; Sanjay Bhagani; Daniel Skiest; Mariam S Aziz; Nichola Cooper; Ivor S Douglas; Sinisa Savic; Taryn Youngstein; Lorenzo Del Sorbo; Antonio Cubillo Gracian; David J De La Zerda; Andrew Ustianowski; Min Bao; Sophie Dimonaco; Emily Graham; Balpreet Matharu; Helen Spotswood; Larry Tsai; Atul Malhotra
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

Review 7.  The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.

Authors:  Marcin F Osuchowski; Martin S Winkler; Tomasz Skirecki; Sara Cajander; Manu Shankar-Hari; Gunnar Lachmann; Guillaume Monneret; Fabienne Venet; Michael Bauer; Frank M Brunkhorst; Sebastian Weis; Alberto Garcia-Salido; Matthijs Kox; Jean-Marc Cavaillon; Florian Uhle; Markus A Weigand; Stefanie B Flohé; W Joost Wiersinga; Raquel Almansa; Amanda de la Fuente; Ignacio Martin-Loeches; Christian Meisel; Thibaud Spinetti; Joerg C Schefold; Catia Cilloniz; Antoni Torres; Evangelos J Giamarellos-Bourboulis; Ricard Ferrer; Massimo Girardis; Andrea Cossarizza; Mihai G Netea; Tom van der Poll; Jesús F Bermejo-Martín; Ignacio Rubio
Journal:  Lancet Respir Med       Date:  2021-05-06       Impact factor: 30.700

8.  Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.

Authors:  Jennifer Tom; Min Bao; Larry Tsai; Aditi Qamra; David Summers; Montserrat Carrasco-Triguero; Jacqueline McBride; Carrie M Rosenberger; Celia J F Lin; William Stubbings; Kevin G Blyth; Jordi Carratalà; Bruno François; Thomas Benfield; Derrick Haslem; Paolo Bonfanti; Cor H van der Leest; Nidhi Rohatgi; Lothar Wiese; Charles Edouard Luyt; Farrah Kheradmand; Ivan O Rosas; Fang Cai
Journal:  Crit Care Med       Date:  2022-03-01       Impact factor: 9.296

Review 9.  The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome.

Authors:  Cristina Rosário; Gisele Zandman-Goddard; Esther G Meyron-Holtz; David P D'Cruz; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-08-22       Impact factor: 8.775

10.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2021-05-01       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.